Noncompaction cardiomyopathy medical therapy
|
Noncompaction Cardiomyopathy Microchapters |
|
Pathophysiology |
|---|
|
Differentiating Noncompaction Cardiomyopathy from other Diseases |
|
Diagnosis |
|
Treatment |
|
Noncompaction cardiomyopathy medical therapy On the Web |
|
Risk calculators and risk factors for Noncompaction cardiomyopathy medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The medical management of noncompaction cardiomyopathy is similar to that of other cardiomyopathies and includes the use of ACE inhibitors, beta blockers and aspirin[1].
Antiplatelet Therapy
Given the risk of embolization, all patients with NCC are generally treated with prophylactic aspirin.
Beta Blockade
Noncompaction cardiomyopathy is assocatiated with an increased risk of arrhythmias including ventricular tachyarrhythmias. Beta blockade may reduce this risk. The impact of Carvedilol on left ventricular function has been reported [2].
Angiotensin Converting Enzyme (ACE) Inhibition
Similar to other cardiomyopathies, ACE inhibitors are indicated given the low cardiac output in these patients.
Calcium Channel Blockade
Calcium channel blockers may be of benefit in those patients with apical hypertrophy and no reduction in systolic contractility.
Patients with Mitochondrial Abnormalities
Some groups have recommended the use of Coenzyme Q10, riboflavin, thiamine and carnitine in these patients.
References
- ↑ Botto, LD. Left ventricular noncompaction. Orphanet encyclopedia. http://www.orpha.net/data/patho/GB/uk-LVNC.pdf
- ↑ Toyono M, Kondo C, Nakajima Y, et al. Effects of carvedilol on left ventricular function, mass, and scintigraphic findings in isolated left ventricular non-compaction. Heart. 2001; 86: e4–e6.